CPNM estadio III: inmunoterapia

17 / 63

Dr. Mark A. SocinskiNSCLC Meta-analysis col cet 2014
NSCLC Meta-analysis Collaborative Group Lancet 2010
Neoadjuvant vs. Adjuvant Chemotherapy: Meta-
Analysis
N HR P value
Neoadjuvant
Trials 2385 0.87
(95% CI 0.78-0.96) .007
Adjuvant Trials 8447 0.86
(95% CI 0.81-0.92) <.0